Sino Biopharm’s Oral Psoriasis Drug TQH3906 Delivers Biologic-Like Efficacy in Phase II Trial

Claim 70% Off TipRanks This Holiday SeasonUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and analysis and maximize your portfolio's potentialSino Biopharmaceutical ( (HK:1177) ) has provided an update. Sino Biopharmaceutical has reported positive Phase II clinical trial results for TQH3906, a Category 1 innovative oral TYK2/JAK1 JH2 allosteric inhibitor developed in-house for the treatment of moderate-to-severe plaque psoriasis. The randomized, double-blind, placebo-controlled multicenter study in 209 patients showed that at the recommended Phase II dose, TQH3906 delivered PASI 75 response rates above 90% and PASI 90 rates above 70% at 12 weeks, far exceeding placebo and demonstrating efficacy comparable to IL-17/IL-23 biologics and superior to currently marketed oral psoriasis drugs in China. Safety outcomes were favorable, with adverse events largely mild and comparable to placebo, and no new safety signals identified, underscoring the potential of TQH3906 to address a clear unmet need for highly effective, convenient oral therapies that can narrow the efficacy gap between small molecules and biologics. By targeting the pseudo-kinase domain to enhance selectivity versus traditional JAK inhibitors, the candidate could strengthen Sino Biopharmaceutical’s competitive position in immunology and dermatology, with the company planning to expand development into additional autoimmune and skin-related indications such as inflammatory bowel disease and psoriatic arthritis. The most recent analyst rating on (HK:1177) stock is a Hold with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page. More about Sino Biopharmaceutical Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on the research, development and commercialization of innovative medicines, with a particular emphasis on small-molecule and biologic therapies for major disease areas including dermatology and autoimmune disorders. YTD Price Performance: 103.42% Average Trading Volume: 76,676,569 Technical Sentiment Signal: Buy Current Market Cap: HK$114.8B Learn more about 1177 stock on TipRanks’ Stock Analysis page.